Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$1.53 USD

1.53
271,876

-0.11 (-6.71%)

Updated Apr 15, 2024 04:00 PM ET

After-Market: $1.53 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Balance Sheet

Research for SPRO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Spero Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 76 109 146 127 82
Receivables 51 1 3 6 9
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 4 3 9 6 5
Total Current Assets 131 114 158 139 95
Net Property & Equipment 0 0 1 2 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 47 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 6 6 5 4
Total Assets 182 125 171 153 106
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 1 1 1 1 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 7 9 14 12 22
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 27 10 2 0 0
Total Current Liabilities 37 22 19 14 27
Mortgages 0 0 0 0 0
Deferred Taxes/Income 34 22 9 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 49 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 76 49 83 21 32
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 498 490 456 410 274
Retained Earnings -391 -414 -367 -278 -199
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 107 76 88 132 75
Total Liabilities & Shareholder's Equity 182 125 171 153 106
Total Common Equity 107 76 88 132 75
Shares Outstanding 53.00 52.40 32.30 27.10 19.10
Book Value Per Share 2.02 1.45 2.73 4.87 3.90

Fiscal Year End for Spero Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 76 94 78 96
Receivables NA 51 3 2 2
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 4 5 9 4
Total Current Assets NA 131 102 88 102
Net Property & Equipment NA 0 0 0 0
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 47 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 6 6
Total Assets NA 182 107 99 113
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 1 1 1 1
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 7 7 6 9
Income Taxes Payable NA 0 2 0 0
Other Current Liabilities NA 27 14 9 12
Total Current Liabilities NA 37 25 17 23
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 34 24 22 20
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 76 53 44 48
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 498 496 494 492
Retained Earnings NA -391 -442 -439 -427
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 107 54 55 65
Total Liabilities & Shareholder's Equity NA 182 107 99 113
Total Common Equity 0 107 54 55 65
Shares Outstanding 53.80 53.00 52.70 52.50 52.50
Book Value Per Share 0.00 2.02 1.02 1.04 1.24